Palantir 1Q26 Accelerates Revenue to +85%, Operating Margin Hits 60%, Yet Valuation Overhang Persists

Core Conclusion

Palantir delivered its strongest revenue growth as a public company—+85% YoY in 1Q26, accelerating for the 11th consecutive quarter, with operating margins reaching 60%. Management raised FY26 revenue growth guidance to +71% from +61%. Despite these best-in-class fundamentals, after-hours stock reaction was flat for the second straight beat-and-raise quarter, indicating the market has fully priced in current momentum. At ~34x CY27 sales and ~56x CY27 FCF, the stock requires sustained high growth to justify the multiple. Maintain Equal-weight and $205 target, implying 40% upside over 2–3 years but limited near-term relative appeal.

What the Market May Be Underestimating

The market likely underestimates Palantir’s ability to sustain acceleration from an already elevated base. Consensus expected +74% YoY; actual print was +85%. The FY26 revenue guidance midpoint of $7,656bn (+71%) represents a +6.5% raise, and the implied 2H26 growth of +63% YoY is conservative relative to 1H26's >+80% pace. However, the market’s muted response suggests that extrapolating these trends further is already embedded in price. The key disconnect is not about near-term growth but about how much future growth is required to support current valuation multiples.

Evidence Chain

1. Revenue growth accelerated to +85% YoY, exceeding consensus by 11pp.

• 1Q26 vs. 4Q25/3Q25/2Q25: +85%, +70%, +63%, +48%.
• Drive: US government accelerated to +76% (from +66%), US commercial grew +133% (moderating from +137%), international government +50% (from +43%), international commercial +26% (from +7%).
• Net dollar retention improved to 150% from 139%; net customer adds rose to 53 from 43.

2. Operating margin expanded 1,650bps to 60% as opex grew only +35% YoY.

• Rule of 40 (growth + margin) jumped to 145% from 127%.
• FY26 operating margin guidance raised to 58% (from 57.5%), above consensus 57.6%.
• Adjusted FCF guidance raised to $4.2–4.4bn, implying 56% margin.

3. FY26 revenue growth guidance raised to +71%, US commercial guided to +120%.

• Underlying US commercial growth target of +120% (up from +115%, comparing to +109% in FY25), reaching $3,224bn.
• Q2 revenue guidance of $1,797–$1,901bn implies +79% YoY; 2H26 implied +63% at the high end of full-year guide—conservative given 1H >+80%.

4. Two consecutive beats have resulted in flat post-earnings stock moves.

• After both 4Q25 and 1Q26 releases, shares were essentially unchanged after hours.
• Current valuation: ~34x CY27 sales, ~56x CY27 FCF. This is among the highest in large-cap software, implying the market expects mid-40% revenue CAGR through CY30.

Key Disagreements & Risks

Valuation premium is unsustainable if growth decelerates. The current multiple embeds >40% CAGR for 5+ years; any base-effect slowdown or competitive pressure would trigger multiple contraction. The law of large numbers is already visible: US commercial TCV bookings growth slowed to +45% from +65%, and remaining deal value growth to +112% from +145%.

Customer concentration and lumpy deal flow. Large transaction uncertainty is high—TCV bookings growth dropped from +192% (RPO bookings, Q4) to +90% in Q1. U.S. commercial TCV bookings growth fell from +65% to +45%. Such volatility reduces revenue visibility.

International expansion lags materially. International commercial grew just +26% (vs. US commercial +133%), suggesting the go-to-market model is not yet replicable outside North America. Without global scaling, the total addressable market is constrained.

Valuation & Trade Implication

Target price $205 is derived from 44x CY30 FCF/share of $6.68, discounted back at 13% WACC. This multiple equals a ~1.12x growth-adjusted EV/FCF/G, in line with large-cap software median of 1.14x. The bull/base/bear framework shows $295/$205/$81. Current $146 offers 40% upside to target, but the path requires 2–3 years of sustained 40%+ revenue growth to compress the multiple to a defensible level. Near-term risk/reward is balanced; we see no trigger to shift from Equal-weight. Any growth disappointment (e.g., 2H26 guidance cut due to deal lumpiness) could cause sharp re-rating.

Appendix Data Summary